Additionally, we systematically review the preclinical and clinical evidence for therapeutic strategies targeting ribosome biogenesis in DLBCL, including conventional chemotherapeutic agents like platinum compounds and anthracyclines, selective RNA polymerase I inhibitors, and XPO1 inhibitors. This evidence concerns the gene XPO1 and diffuse large B-cell lymphoma.